Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Y-mAbs Therapeutics (YMAB) Misses Q3 EPS by 6c
November 4, 2021 4:49 PM EDTY-mAbs Therapeutics (NASDAQ: YMAB) reported Q3 EPS of ($0.66), $0.06 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $9 million versus the consensus estimate of $10.87 million.
For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.
... More